We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $624M
1-Year Est. Return 250.2%
This Fund
S&P 500
This Quarter Est. Return
+7.61%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$502M
AUM Growth
-$22.7M
Cap. Flow
+$19.2M
Cap. Flow %
3.83%
Top 10 Hldgs %
48.75%
Holding
84
New
17
Increased
18
Reduced
14
Closed
28

Top Buys

Rank Stock Value
1
JBIO
Jade Biosciences
JBIO
+$38.4M
2
ISRG icon
Intuitive Surgical
ISRG
+$14.2M
3
RGEN icon
Repligen
RGEN
+$13.6M
4
GMAB icon
Genmab
GMAB
+$13.3M
5
HNGE
Hinge Health
HNGE
+$13M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$16.1M
2
HUM icon
Humana
HUM
+$13.3M
3
GKOS icon
Glaukos
GKOS
+$13.2M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$9.93M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$9.48M

Sector Composition

Rank Sector Weight
1 Healthcare 99.37%
2 Miscellaneous 0.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NAMS icon
76
NewAmsterdam Pharma
NAMS
$2.69B
– –
-68,000
Closed -$1.39M
NBIX icon
77
Neurocrine Biosciences
NBIX
$14.9B
– –
-85,700
Closed -$9.48M
PCVX icon
78
Vaxcyte
PCVX
$8.65B
– –
-23,000
Closed -$868K
REGN icon
79
Regeneron Pharmaceuticals
REGN
$80.8B
– –
-25,400
Closed -$16.1M
RGNX icon
80
Regenxbio
RGNX
$530M
– –
-260,000
Closed -$1.86M
RPRX icon
81
Royalty Pharma
RPRX
$26B
– –
-87,000
Closed -$2.71M
UTHR icon
82
United Therapeutics
UTHR
$21.2B
– –
-16,800
Closed -$5.18M
VERA icon
83
Vera Therapeutics
VERA
$2.45B
– –
-91,000
Closed -$2.19M
XBI icon
84
State Street SPDR S&P Biotech ETF
XBI
$10.6B
– –
-94,000
Closed -$7.62M
1 2 3
4

Similar funds

DCM
Davidson Capital Management Corpus Christi, Texas $624M AUM 29.17% 1-Year Est. Return
SIG
Spinnaker Investment Group Newport Beach, California $624M AUM 17.54% 1-Year Est. Return
PFA
Pettinga Financial Advisors Evansville, Indiana $624M AUM 24.87% 1-Year Est. Return
ANB
Amarillo National Bank Amarillo, Texas $624M AUM 20.28% 1-Year Est. Return
CWM
Chemistry Wealth Management New York $625M AUM 19.32% 1-Year Est. Return
RIP
RAM Investment Partners Bellevue, Washington $625M AUM 16.29% 1-Year Est. Return
TAM
Third Avenue Management New York $625M AUM 48.93% 1-Year Est. Return
B
Bellecapital Zurich, Switzerland $625M AUM 39.69% 1-Year Est. Return

Avidity Partners Management's Q2 2025 Portfolio in Review

As of Q2 2025, Avidity Partners Management held 84 positions worth $502M, down 4.3% from $525M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Avidity Partners Management deployed $19.2M of net new capital in Q2 2025, opening 17 new positions and adding to 18 existing holdings. Its largest new stake was Jade Biosciences: 1,127,186 shares worth $11.3M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 91% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Humana, an estimated $13.3M trimmed.

  • Avidity Partners Management's largest Q2 2025 buy was Jade Biosciences: 1,127,186 shares worth $11.3M.
  • Avidity Partners Management added most to CG Oncology in Q2 2025, an estimated $12.5M increase.
  • Avidity Partners Management's biggest Q2 2025 reduction was Humana, cutting an estimated $13.3M.
  • Avidity Partners Management fully exited Regeneron Pharmaceuticals in Q2 2025, selling an estimated $16.1M.
  • Avidity Partners Management's ten largest holdings make up 49% of its $502M portfolio in Q2 2025.
  • Avidity Partners Management opened 17 new positions and closed 28 in Q2 2025.
  • Avidity Partners Management's portfolio value fell 4.3% quarter-over-quarter to $502M.

Based on Avidity Partners Management's 13F filing for Q2 2025, filed 14 Aug 2025.